

# Genetic Regulation of Gene Expression in HIV+ T Cells and Monocytes Associated With Control of HIV



Riley H. Tough<sup>1,2</sup>, Shanelle Gingras<sup>1,2</sup>, David M. Tang<sup>1</sup>, Jeffrey F. Tuff<sup>1</sup>, Catherine M. Card<sup>1</sup>, Paul J. McLaren<sup>1,2</sup> <sup>1</sup>National HIV and Retrovirology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba <sup>2</sup>Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Canada

#### Purpose


To investigate how human genetic variability in highly HIV affected populations modifies viral load and disease progression. From a better understanding of the HIV host-pathogen interaction, we aim to help guide the development of hosttargeted HIV therapeutics.



Conflict of Interest Disclosure: I have no conflicts of interest

### Contact: Riley Tough; toughr@myumanitoba.ca

### Background




A genome-wide association study with 3,879 individuals of African ancestry, conducted by our lab, identified a region of chromosome 1 significantly associated with decreased HIV setpoint viral load (spVL).

Variants in high linkage disequilibrium, shown in orange and red, to the top associated SNP (rs59784663, p < 5E-10) overlaps three coding genes: *PRKAB2*, *FMO5*, and *CHD1L*.

*CHD1L* is involved in chromatin relaxation and DNA repair<sup>1</sup>. *PRKAB2* is a regulatory scaffold for the AMPK complex, a master regulator kinase for low-energy states<sup>2</sup>. *FMO5* is part of the flavin-monooxygenase family of genes that metabolise drugs, however *FMO5* appears to lack this ability<sup>3</sup>.

The top associated variant is only present in African populations (4-12% minor allele frequency by geographic region) and not present in European or Asian populations (minor allele frequency < 1%). This provides support why this region has not been detected in similar studies with individuals of European or Asian ancestry.

Statistical fine-mapping of variants in linkage disequilibrium ( $R^2>0.6$ ) to rs59784663 implicates rs73004025 and rs7519713 as the likely causal for driving changes to gene expression.



#### Allelic dosage of rs73004025 and rs7519713

# Hypotheses

1. Individuals, carrying the variant rs59784663, will have differential gene and protein expression of *CHD1L, FMO5,* and/or *PRKAB2*.

2. Gene expression of *CHD1L, FMO5,* and/or *PRKAB2* will be higher in individuals carrying the alternate allele at the top associated SNP.


## Objectives

1. Sort cryopreserved HIV+ PBMCs from individuals of African ancestry that carry the various alleles at the top associated SNP into CD4+ T cell and monocyte fractions.

2. Determine whether rs59784663 is associated with differential gene expression of *CHD1L*, *FMO5*, and/or *PRKAB2* in CD4+ T cells and monocytes.


3. Determine whether gene expression pathways associated with *CHD1L*, *FMO5*, and/or *PRKAB2* are differentially expressed in CD4+ T cell fractions.

# Methods




#### Results


# Differential gene expression in <u>unstimulated CD4+ T cells</u> normalized against TBP, RPL13A, and SDHA expression




Relative gene expression was calculated using multiple housekeeping genes for CD4+ T cells and monocytes as previously described<sup>5,6</sup>.


We detected no significant differences in CD4+ T cells (N=21). There was a trend for higher *CHD1L* expression in stimulated CD4+ T cells of individuals carrying the reference allele but this was not statistically significant (p < 0.15).














There is a non-significant trend (p < 0.11) that *CHD1L* has decreased expression in individuals with the variant allele in monocytes (N=12). Increasing the sample size may improve our power to determine significant differences.



# Genetic Regulation of Gene Expression in HIV+ T Cells and Monocytes Associated With Control of HIV



# Results – RNA Sequencing

We used RNA-sequencing to ask whether *CHD1L*, *PRKAB2*, and/or *FMO5* are likely to act in a signalling cascade. If these genes are modulating pathway expression, genes acting downstream of *CHD1L*, *PRKAB2*, or *FMO5* would likely have differential expression.

Stimulated CD4+ T cells		
Gene ID	Log2FC	Adj P-value*
STAG3L1	0.61	0.036
PRKAB2	0.14	0.995
FMO5	-0.09	0.995
CHD1L	-0.06	0.995

Unstimulated CD4+ T cells		
Gene ID	Log2FC	Adj P-value*
ITM2B	-0.19	0.036
PRKAB2	0.08	0.999
FMO5	0.23	0.999
CHD1L	0.14	0.999

\*adjustment using Bonferonni correction

We observed no significant differences in expression of *CHD1L*, *PRKAB2*, or *FMO5* in stimulated or unstimulated CD4+ T cells (N=21).

We observed no significant differences in gene expression for genes in pathways associated with *CHD1L*, *PRKAB2*, or *FMO5*.

#### Summary

- 1. There were no significant differences of *CHD1L, PRKAB2,* or *FMO5* expression in CD4+ T cells (N=21) or monocytes (N=12)
- 2. There is a non-significant trend (p < 0.15) for <u>decreased *CHD1L* expression</u> in stimulated CD4+ T cells and monocytes of individuals <u>carrying the variant allele</u>
- 3. There is no significant difference in expression pathways downstream of genes in the chromosome 1 region
- 4. It is unlikely that gene expression changes in CD4+ T cells are driving decreased HIV spVL

## References

- 1. Ahel et al. *Science*. 2009.
- 2. Thornton et al. *The Journal of Biological Chemistry*. 1998.
- 3. Scott et al. Drug Metabolism and Disposition. 2017.
- 4. Christiaan A. de Leeuw et al. *Plos Computational Biology*. 2015.
- 5. Vandesompele et al. *Genome Biology*. 2002.
- 6. Hellemans et al. *Genome Biology*. 2007

## Contact: Riley Tough; toughr@myumanitoba.ca